Vicore to Present at the Oppenheimer Movers in Rare Disease Summit

About this update from Vicore Pharma Holding Ab

[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / December 5, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Oppenheimer Movers in Rare Disease Summit:","length":277,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Location: New York, USA","length":23,"tagName":"p"}]},{"val":[{"type":"text","content":"Format: Fireside Chat and 1×1 meetings","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Date and Time: Thursday, December 11 at 9:00 AM ET","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Participant: Megan Richards, VP of IR, Communications, and Portfolio Strategy","length":77,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":201,"olType":false},{"type":"text","content":"The company's management team will also be available for meetings at the conference.","length":88,"tagName":"p"},{"type":"text","content":"For more information, please contact:Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected] Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]","length":231,"tagName":"p"},{"type":"text","content":"About Vicore Pharma Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.","length":584,"tagName":"p"},{"type":"text","content":"The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com","length":92,"tagName":"p"},{"type":"text","content":"AttachmentsVicore to present at the Oppenheimer Movers in Rare Disease Summit","length":78,"tagName":"p"},{"type":"text","content":"SOURCE: Vicore Pharma Holding","length":29,"tagName":"p"},{"type":"text","content":"View the original press release on ACCESS Newswire","leng...

More updates from Vicore Pharma Holding Ab